Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Encorafenib and Binimetinib in Advanced Solid Tumors
NCT03864042Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of encorafenib and binimetinib in melanoma and solid tumor (3 arms), sponsored by Pfizer. Primary endpoints: Maximum Concentration (Cmax) of Plasma Midazolam and Metabolites (1-OH Midazolam, Glucuronide Conjugated) at Day 14, Maximum Concentration (Cmax) of Plasma Caffeine and Paraxanthine at Day 14 and 11 more. Started Jan 2018; status: completed.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanomasolid tumor
Beyond the preview
Go deeper on NCT03864042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03864042.